To include your compound in the COVID-19 Resource Center, submit it here.

GPC chronicles

GPC chronicles

GPC (FSE:GPC; GPCB), which was founded in 1997, originally was a genomics- and proteomics-based drug discovery company focused on oncology, infectious diseases and immunology. Since it in-licensed Orplatna satraplatin in 2002, its focus has turned to oncology drug discovery and development. At March 31, GPC had E111.3 million ($148.8 million) in cash. The weekly stock price for GPC is tracked below against selected events since the company's IPO on the Neuer Markt of the Frankfurt Stock Exchange in

Read the full 792 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE